文献速递甲状腺疾病

赖氨酰氧化酶在BRAF/MAPK通路驱动的甲状腺癌侵袭性中起关键作用

Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.
PubMed 文献 · Thyroid · 2018-12-28

本研究探讨赖氨酰氧化酶(LOX)是否介导BRAF/MAPK通路激活在甲状腺癌中的作用。分析TCGA和独立队列发现,BRAF突变肿瘤中LOX表达更高,高LOX表达者无病生存期更短;体外和小鼠模型证实抑制BRAF/MEK降低LOX表达,过表达突变BRAF增加LOX表达,抑制BRAFV600E可减少肿瘤负荷及LOX和p-ERK表达。提示BRAFV600E肿瘤中高LOX表达与更具侵袭性疾病相关。

要点

  • BRAF突变甲状腺癌中LOX表达显著升高,高LOX表达提示无病生存期更短。
  • 抑制BRAFV600E和MEK可降低LOX表达,过表达突变BRAF则增加LOX表达。
  • BRAFV600E小鼠甲状腺肿瘤中LOX和p-ERK强表达,抑制BRAFV600E可减少肿瘤负荷及二者表达。

核心结论

  • BRAFV600E肿瘤中高LOX表达与更具侵袭性的疾病相关。
  • BRAF和MAPK通路调控LOX表达,为临床发现提供生物学基础。

研究设计与样本

  • 在TCGA队列和独立队列中分析LOX的预后价值及其与BRAF突变的关系。
  • 使用突变BRAF和MAPK通路抑制、突变BRAF过表达以及BRAFV600E小鼠模型检测对LOX表达的影响。

主要发现

  • TCGA队列中,BRAF突变肿瘤的LOX表达高于野生型肿瘤(p < 0.0001)。
  • TCGA队列中,BRAF突变且高LOX表达患者无病生存期短于BRAF突变且低LOX组(p = 0.03)。
  • 独立队列中,LOX与BRAF突变细胞百分比呈显著正相关,且高LOX表达与较短无病生存期相关(p = 0.01)。
  • 抑制BRAFV600E和MEK降低LOX表达,过表达突变BRAF增加LOX表达。
  • 甲状腺特异性表达BRAFV600E的小鼠肿瘤组织中LOX和p-ERK强表达;在转基因和原位小鼠模型中抑制BRAFV600E显著减少肿瘤负荷及LOX和p-ERK表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The BRAFV600E mutation is the most common somatic mutation in thyroid cancer. The mechanism associated with BRAF-mutant tumor aggressiveness remains unclear. Lysyl oxidase (LOX) is highly expressed in aggressive thyroid cancers, and involved in cancer metastasis. The objective was to determine whether LOX mediates the effect of the activated MAPK pathway in thyroid cancer. METHODS: The prognostic value of LOX and its association with mutated BRAF was analyzed in The Cancer Genome Atlas and an independent cohort. Inhibition of mutant BRAF and the MAPK pathway, and overexpression of mutant BRAF and mouse models of BRAFV600E were used to test the effect on LOX expression. RESULTS: In The Cancer Genome Atlas cohort, LOX expression was higher in BRAF-mutant tumors compared to wild-type tumors (p < 0.0001). Patients with BRAF-mutant tumors with high LOX expression had a shorter disease-free survival (p = 0.03) compared to patients with a BRAF mutation and the low LOX group. In the independent cohort, a significant positive correlation between LOX and percentage of BRAF mutated cells was found. The independent cohort confirmed high LOX expression to be associated with a shorter disease-free survival (p = 0.01). Inhibition of BRAFV600E and MEK decreased LOX expression. Conversely, overexpression of mutant BRAF increased LOX expression. The mice with thyroid-specific expression of BRAFV600E showed strong LOX and p-ERK expression in tumor tissue. Inhibition of BRAFV600E in transgenic and orthotopic mouse models significantly reduced the tumor burden as well as LOX and p-ERK expression. CONCLUSIONS: The data suggest that BRAFV600E tumors with high LOX expression are associated with more aggressive disease. The biological underpinnings of the clinical findings were confirmed by showing that BRAF and the MAPK pathway regulate LOX expression.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Boufraqech M, Patel D, Nilubol N, et al. Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. Thyroid. 2018. PMID: 30398411. doi:10.1089/thy.2018.0424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。